UV Light Therapy Shows Promise in Hospitalized COVID Patients

A new double-blinded, randomized, placebo-controlled pilot study observed decreased mortality for COVID-19 patients who received narrowband UVB phototherapy treatments compared to a placebo. 28-day mortality was 13.3% in the treatment group vs. 33.3% in the placebo group.

Read more about this research: https://onlinelibrary.wiley.com/doi/10.1111/exd.14617

SOLIUS® devices are not cleared or approved for the indication to treat and/or prevent COVID-19. SOLIUS devices are intended only to stimulate the production of endogenous vitamin D for the treatment and prevention of vitamin D deficiency. Please review the important safety information associated with SOLIUS therapy.